It is time for these companies to pay their fair share in the US, rather than using lobby firms to continually kick the can, down the alley -- decade after decade. And given this morning's antitrust settlement -- it is time for them to stop gaming the US patent system, to prevent generic entrants for decades at a time as well. Here is what Rahway spent on -- in Q1 2023:
. . .H.R. 830, Help Ensure Lower Patient (HELP) Copays Act; H.R. 1418, Animal Drug User Fee Amendments of 2023; H.R. 1503, Prescription Information Modernization Act of 2023; H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021; H.R. 2873, (117th Cong.) Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; H.R. 3932/S. 2076, (117th Cong.) Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021; S. 150, Affordable Prescriptions for Patients Act of 2023; S. 1712, (116th Cong.) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; S. 2076, (117th Cong.) Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2021 or the PASTEUR Act of 2021; S. 1895 (116th Congress) Lower Health Care Costs Act; S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; S. 4760, (116th Congress) The PASTEUR Act. . . .
Issues relating to:
340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms -- international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Prescription drug cost-sharing; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; Intellectual property and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Pharmacy Benefit Manager (PBM) policy issues. . . .
H.R. 5376, (117th Cong.) Build Back Better Act; S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
Issues relating to:
Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; FY-2023 Budget and Appropriations Legislation.. . . .
Issues related to: Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Inflation Reduction Act (P.L. 117-169), provisions relating to taxes. . . .
Now you know. . . onward, grinning.
नमस्ते
No comments:
Post a Comment